Crossmark

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients

Crossref DOI link: https://doi.org/10.1186/s12981-016-0091-1

Published Online: 2016-02-10

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Hongwei

Jin, Ronghua

Yao, Cheng

Zhang, Tong

Wang, Meixia

Xia, Wei

Peng, Haiyan

Wang, Xiaojuan

Lu, Rongjian

Wang, Changjin

Xie, Dong

Wu, Hao
Funding

Funding for this research was provided by:

the Ministry of Science and Technology of China (D141100000314005)

the Ministry of Science and Technology of China (D141100000314002)

the national "twelfth five" major projects of AIDS and viral hepatitis and other major infectious diseases prevention and control (2012ZX10001-003)

the Beijing Municipal Science & Technology Commission (D131100005313005)